^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Padcev (enfortumab vedotin-ejfv) (Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Published date:
05/25/2023
Excerpt:
MVA of this large, multi-site, retrospective cohort of aUC pts, identified several putative biomarkers independently associated with EV treatment outcomes. Longer OS was associated with ERBB2 and KDM6A alts, low PD-L1 and high TMB.
DOI:
10.1200/JCO.2023.41.16_suppl.4573
Source:
Title:
Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Published date:
02/13/2023
Excerpt:
For all pts, ORR 47%, mPFS 6 mos, mOS 12 mos....Shorter mPFS was noted in pts with CDKN2A, CDKN2B, and MTAP alts, and longer mOS in pts with high TMB...This large, multi-site, retrospective cohort of pts with aUC identified several potential biomarkers associated with differential outcomes to EV.
DOI:
10.1200/JCO.2023.41.6_suppl.450
